Accessibility Menu
Mymetics logo

Mymetics(OTC) MYMX

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
Mymetics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-11
Mymetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-02-18
1 month+0%USD 0.002026-02-18
3 month+0%USD 0.002026-02-03
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-04-24
3 year-100%USD 15.202023-05-12
5 year-100%USD 227.602021-05-12
Since inception-100%USD 5,000.002001-03-29

Mymetics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€359.66K

Net Income (TTM)

-€11.57M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

101

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

May 15, 2023

MYMX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mymetics

Mymetics Corporation is a Swiss biotechnology company focused on developing innovative vaccines to combat infectious diseases. The company has a diverse pipeline that includes vaccine candidates for HIV-1/AIDS, COVID-19, and malaria, among others. Collaborations with leading research institutions enhance its capabilities in vaccine development.

Products and Services
  • Vaccine candidates for HIV-1/AIDS and COVID-19
  • Intranasal influenza and respiratory syncytial virus (RSV) vaccines
  • Virosome-based formulations for malaria transmission-blocking
Growth Outlook
  • Strong partnerships with institutions like Texas Biomedical Research Institute
  • Focus on developing vaccines for high-impact infectious diseases
  • Potential market expansion as vaccine needs grow globally
Financial Highlights
  • Q3 2023 revenue of 36,986 EUR, a decrease from Q2
  • Net income for Q3 2023 was -1,114,000 EUR
  • Cash and cash equivalents at 62,000 EUR as of September 30, 2023
Mymetics Corporation operates in a critical sector, addressing significant health challenges through its vaccine development initiatives. The company's collaborations with prominent research institutions position it well for future advancements in vaccine technology. Despite recent financial challenges, including a net loss in the latest quarter, the ongoing focus on high-demand vaccine candidates may provide opportunities for growth as global health needs evolve. Investors may find Mymetics Corporation's innovative approach and strategic partnerships noteworthy as the biotechnology landscape continues to expand.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Employees

8

CEO

Ronald Hugo Gerard Kempers, MBA

Headquarters

Epalinges, VD 1066, CH

MYMX Financials

Key Financial Metrics (TTM)

Gross Margin

-47966.67%

Operating Margin

-58166.67%

Net Income Margin

-160166.67%

Return on Equity

7.69%

Return on Capital

-24.57%

Return on Assets

-65.63%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

101

Avg. Volume

1.629

Financials (TTM)

Gross Profit

-€762.01K

Operating Income

-€2.36M

EBITDA

-€8.73M

Operating Cash Flow

-€1.74M

Capital Expenditure

€34.97

Free Cash Flow

-€1.74M

Cash & ST Invst.

€62.00K

Total Debt

€75.11M

Mymetics Performance Analysis

Mymetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31EUR 508,252N/A
20222022-12-31EUR 1,080,402112.6%
Mymetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-9.0%
Q12023-03-31-97.5%
Q22023-06-306611.4%
Q32023-09-30-81.6%
Mymetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31EUR -36.81N/A
20222022-12-31EUR -33.25-9.7%
Mymetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-3141.3%
Q12023-03-3129.5%
Q22023-06-30-716.1%
Q32023-09-30-28872.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

€36.99K

-71.5%

Gross Profit

-€23.01K

+70.9%

Gross Margin

-62.22%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

-€1.11M

+51.4%

EBITDA

-€401.00K

+37.2%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

€62.00K

-84.5%

Total Debt

€75.11M

+5.2%

Accounts Receivable

€13.00K

-77.6%

Inventory

€0.00

N/A

Long Term Debt

€145.00K

-37.8%

Short Term Debt

€74.97M

+5.3%

Return on Assets

-65.63%

N/A

Return on Invested Capital

2.70%

N/A

Free Cash Flow

-€335.00K

+38.2%

Operating Cash Flow

-€335.00K

+38.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACUSAcusphere, Inc.
$0.00+0.00%
LGBICannabiz Mobile, Inc.
$0.00+0.00%
APYIAspyra Inc.
$0.00+0.00%
SECISector 10, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About MYMX

What is the current price of Mymetics?

Mymetics is trading at $0.00 per share.

What is the 52-week range for Mymetics?

Over the past 52 weeks, Mymetics has traded between $0.00 and $0.00.

How much debt does Mymetics have?

As of the most recent reporting period, Mymetics reported total debt of €76.84M.

How much cash does Mymetics have on hand?

Mymetics reported €334.05K in cash and cash equivalents in its most recent financial results.

What is Mymetics’s dividend yield?

Mymetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.